Oxbryta (sickle cell drug withdrawal)
Oxbryta, a sickle cell medicine, was withdrawn in 2024 after data showed more pain crises and deaths among users. Legal activity is limited, and we are tracking it.
- Court
- Individual cases (reported coordination in N.D. California)
We're not accepting review requests here
No MDL; small number of individual federal cases. Pfizer withdrew Oxbryta in Sept 2024 and said in Aug 2026 there is no viable path to return it to the U.S. market.
See campaigns accepting reviewsWhere things stand
- Sep 2024Pfizer voluntarily withdrew Oxbryta worldwide; FDA alerted patients and providers.
- Aug 4, 2026Pfizer letter: after FDA engagement, no viable path to make Oxbryta available again in the U.S.
Records that usually help
You don't need these to start. Don't upload them here — a firm will ask if it needs them.
- Pharmacy records for Oxbryta
- Hospital admission records for crises or stroke
- Hematology records
- Death certificate if applicable
About filing deadlines
Deadlines to file a claim vary by state and situation, and some may already have passed. Only a licensed attorney can tell you whether a deadline applies to you. Submitting here does not stop any deadline.
Attorney advertising. TortMatics (FusionByte Media LLC) is not a law firm. Information on this page is general and is not medical or legal advice. Talk to a doctor before changing any medication.